How Ozempic Works for Weight Loss
Ozempic (semaglutide) is a GLP-1 receptor agonist developed by Novo Nordisk. It mimics the incretin hormone GLP-1 to regulate blood sugar and appetite. The drug activates GLP-1 receptors in the brain, slowing gastric emptying and promoting satiety. This reduces caloric intake without requiring extreme willpower. Ozempic is approved for type 2 diabetes, but its weight loss effects have driven off-label demand and insurance debates. For financial context, Novo Nordisk's market cap reached over $500 billion in 2024, reflecting investor focus on GLP-1 drugs. Learn why Novo Nordisk became Europe's most valuable company.
Semaglutide binds to GLP-1 receptors in the hypothalamus and brainstem. This reduces hunger signals and increases feelings of fullness. The drug also delays gastric emptying, making meals feel longer-lasting. Clinical trials showed average weight loss of 14.9% of body weight over 68 weeks at the 2.4 mg maintenance dose. The STEP 1 trial, published in the New England Journal of Medicine, involved 1,961 adults with obesity or overweight with weight-related conditions. Read the STEP 1 trial summary. These results are why GLP-1 drugs are now central to obesity pharmacotherapy.
Ozempic Dosage and Administration for Weight Loss
Ozempic is administered as a once-weekly subcutaneous injection. The starting dose is typically 0.25 mg for 4 weeks, then 0.5 mg for at least 4 weeks. The maintenance dose for weight management is often 2.4 mg, though this is the Wegovy formulation. Off-label use for weight loss may involve lower doses. Common side effects include nausea, vomiting, diarrhea, and constipation. These usually decrease over time as the body adjusts. FDA Ozempic label and safety information.
Real-world usage shows that adherence to the dosing schedule is critical. Missed doses can blunt weight loss results. Patients often combine Ozempic with lifestyle changes, including calorie-controlled diets and exercise. Some clinics offer compounded semaglutide as a lower-cost alternative, though these products lack FDA approval for consistency and safety. Insurance coverage varies widely, with many plans requiring prior authorization and documentation of obesity-related comorbidities. Novo Nordisk annual report 10-K filing with the SEC.
Ozempic Weight Loss Results and Market Impact
In clinical trials, participants lost an average of 14.9% of their initial body weight on semaglutide 2.4 mg. Some individuals lost 20% or more. Weight regain is common after stopping the drug, with studies showing partial or full reversal within a year. The financial impact is significant. Global GLP-1 receptor agonist sales are projected to exceed $100 billion annually by 2030.